Abstract
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disease, and both genetic and environmental etiologies contribute to its pathogenesis (1, 2) . Mutations in the gene LRRK2 (leucine-rich repeat kinase) are the most common genetic cause of PD. They account for around 15% of familial and 5% of sporadic cases of PD (3, 4) . The LRRK2 gene encodes a 2527 amino acid protein that plays a role in signaling pathways regulating neurite and synaptic morphology as well as controlling microRNA-mediated translational regulation (5) (6) (7) (8) (9) (10) (11) (12) (13) . LRRK2 has kinase, GTPase as well as several other protein domains (14) (15) (16) . One possible mechanism of toxicity that has gained support is by a pathological increase in its kinase activity, which occurs with several of the most common mutations (14) ; the pharmacological inhibition of this kinase activity was shown to be protective against nigral cell death mediated by viral-induced expression of mutant LRRK2 (8) . LRRK2-associated PD manifests with a clinical picture indistinguishable from sporadic PD, but the pathology shows a variable phenotype, including tau-positive neurofibrillary tangles (NFT) (3) (4) (5) (6) 17) .
The microtubule-associated protein tau forms neurofibrillary tangles in several neurodegenerative diseases termed tauopathies, which include Alzheimer's disease (AD), Pick's disease, corticobasal degeneration and primary supranuclear palsy (18, 19) . Mutations in the tau gene were demonstrated to be a direct cause of neurodegeneration in the syndrome of frontotemporal dementia with parkinsonism linked to chromosome 17 . Tau is an axon-enriched protein that binds to and stabilizes microtubules and plays a role in organelle trafficking (18, 20) . It also regulates the postsynaptic targeting of the protein fyn, thereby coupling it to N-methyl--aspartate receptor excitability (21) . Hyperphosphorylated tau inclusions occur in PD patients and may be more common in LRRK2 patients (5, 6, (22) (23) (24) (25) (26) . Importantly, variation in the tau gene has been confirmed in many human genome-wide association studies (GWAS) as the second most important genetic risk factor for PD after α-synuclein (27) (28) (29) (30) . A recent study in mice linked tau deficiency to SNpc cell death and dopaminergic neuron degeneration (31) . In a study with conditional LRRK2 expression in forebrain neurons, LRRK2 interacted with α-synuclein to increase its aggregation and accelerate neuropathology (32) . A recent study, however, failed to show an exacerbation of α-synuclein pathology with conditional expression of LRRK2 in the brainstem (33) .
Recent in vitro studies showed that LRRK2 toxicity requires the presence of α-synuclein (34) . In LRRK2 iPS cells, there is an increased expression of α-synuclein (35) , which is also seen in LRRK2-transfected cells, together with an increased α-synuclein aggregation (36, 37) . Despite these findings, none of the transgenic models carrying LRRK2 mutations described thus far has shown Lewy bodies or α-synuclein deposits, whereas several exhibit phospho-tau-positive neurites (8, 32, (38) (39) (40) (41) . LRRK2 does not directly phosphorylate tau in in vitro kinase assays (42) , but it is hypothesized that it may do so indirectly by regulating one or more of the tau kinases and/or phosphatases. There is evidence suggesting that LRRK2 directly phosphorylates TAOK3, a protein homologous to MARKK (microtubule affinityregulating kinase-activating kinase), a kinase/activator of MARK (microtubule affinity-regulating kinase), and itself an important tau kinase (43) .
Whether LRRK2 is an important regulator of tau phosphorylation and aggregation in vivo is not known and whether LRRK2 and tau, being two of the most important genes involved in PD, function in similar or independent pathways to cause disease is also not known. Recent studies in Drosophila and Caenorhabditis elegans suggest that LRRK2 and tau can indeed interact to exacerbate neuronal pathology. In a Drosophila model of LRRK2 G2019S, degeneration of dendrites was exacerbated by tau overexpression and rescued by tau reduction (44) . Tau overexpression increased microtubule fragmentation and inclusions and activated GSK3β (Sgg in Drosophila) was implicated in mediating this interaction. In a C. elegans model, co-expressing LRRK2 R1441C or LRRK2 G2019S with tau V337M increased motor deficits seen in tau V337M worms (45) and exacerbated protein oxidation and lipid peroxidation (46) . An interaction between LRRK2 and tau, however, has not been investigated in a mammalian model to date. We investigated whether an interaction occurs by creating a mouse model that carries both the LRRK2 R1441G and the tau P301S mutations. We found that co-expressing mutant LRRK2 and mutant tau did not induce nigrostriatal pathology nor did it increase tau hyperphosphorylation and aggregation, or exacerbate the behavioral, pathological and biochemical abnormalities which occur in the tau P301S mice.
Results
Phenotype onset, progression and survival are not altered in LRRK2/tau double transgenic mice
To investigate the possible interaction between LRRK2 and tau in a mammalian system in vivo, we crossbred LRRK2 R1441G BAC mice (38) with P301S tau mice (PS19 line) (47) . LRRK2 R1441G mice carry the human LRRK2 gene harboring the R1441G mutation on a bacterial artificial chromosome with its natural promoter (38) . Tau P301S mice carry the human tau gene with the pathogenic mutation P301S under control of the mouse prion protein promoter which imparts a preferential brain expression (47) . Hemizygous LRRK2 R1441G were bred with hemizygous tau P301S mice producing litters composed of the four groups of genotypes at the expected Mendelian ratios of 25% each: wild-type (WT); LRRK2 R1441G transgenic; tau P301S transgenic; and LRRK2 R1441G/tau P301S double transgenic mice. Mutant tau P301S mice start to show hyperactive behavior at around 3 months of age (48, 49) . At around 6 months, the mice develop limb retraction and clasping, which then leads to prominent hindlimb paralysis at 7-10 months. They die prematurely due to brain and spinal cord degeneration, and an inability to properly ambulate and feed, with most mice not surviving after 12 months of age (47) . To assess the behavioral impact of the cross between mutant LRRK2 and tau mice, we assessed the proportion of mice that developed clasping or paralysis monthly, starting from 5 months of age until 10 months of age. Tau P301S mice and LRRK2 R1441G/tau P301S double transgenic mice became paralyzed at similar rates, and no significant difference was found in the percentage of paralyzed mice at any time point of testing (Fig. 1A) . None of the WT or LRRK2 R1441G mice developed clasping or paralysis during the study. We also assessed survival in the different groups. The tau P301S and LRRK2 R1441G/tau P301S mice fared similarly and there was no significant difference in survival as assessed by log-rank test analysis (Fig. 1B) . Mice which were deemed terminal and not able to survive more than 10 days were sacrificed and had their tissues collected. Survival of LRRK2 R1441G mice was similar to WT mice until 15 months of age, the end-point of our study. These combined results show that LRRK2 does not influence the behavioral phenotype or the survival of the tau P301S mice.
LRRK2/tau double transgenic mice do not show worsening of motor or memory abilities
We examined whether mutant LRRK2 interacts with mutant tau to exacerbate motor and memory deficits. We assessed motor performance using openfield and rotarod testing every month, starting from 5 months of age and until 10 months. On openfield testing, no difference was found between the four groups in terms of total distance traveled, average velocity or number of rearings at 6 months or monthly afterwards ( Fig. 2A-C) . Tau P301S and LRRK2 R1441G/tau P301S mice which were paralyzed were excluded from testing. On rotarod testing, there was also no difference in performance between tau P301S and LRRK2 R1441G/tau P301S mice even during until later months (Fig. 2D) , showing there was not even a subtle difference in their performance (again when excluding grossly paralyzed mice).
Tau P301S mice were previously shown to have memory deficits on fear conditioning and on the Morris water maze (48, 49) . At 9 months of age, we assessed performance of the mice on the fear conditioning test, a test which, unlike the Morris water maze, does not necessitate intact motor skills and thus could be performed at an older age when many of the mice have developed paralysis. This test assesses the ability of the mice to remember that they were previously given a mild electric shock, to which they react by freezing when put in the same context or when presented with the same cue that was paired with the shock. The four groups of mice performed similarly on the first day of conditioning, when they were first exposed to the cue followed by the shock (Fig. 3A) . On contextual testing on the second day and on cued testing on the third day, there was no difference between tau P301S and LRRK2 R1441G/tau P301S mice ( Fig. 3B and C) . These results show that the combination of pathogenic mutations in LRRK2 and tau mice does not worsen memory. A previous study showed a very subtle impairment in contextual memory testing in tau P301S (49), but we could not replicate this finding in our study. These findings demonstrate that Openfield and rotarod testing showed no significant differences between the studied groups. There was no difference in total distance traveled, average velocity or number of rearings between the four groups of mice at 6, 7, 8 and 9 months (A-C) (P-value = 0.889, 0.899, 0.869, respectively). (D) The time spent on the rotarod (in s) was not different between the four groups of mice (P-value = 0.617). Grossly paralyzed mice were excluded from testing. Data are plotted as mean ± SEM. Statistical analysis was performed using ANOVA, followed by Tukey's post-hoc test.
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Tau phosphorylation and aggregation found in P301S tau mice are not altered by the overexpression of R1441G LRRK2
A subset of PD patients with LRRK2 mutations show NFTs (5, 6, 23) , and several rat, mouse and Drosophila models develop taupositive inclusions as the most frequent and severe pathology in the central nervous system (8, (38) (39) (40) 44) . It was therefore suggested that LRRK2 may cause its pathogenic effects by regulating tau phosphorylation and aggregation (43, 44, 50) . We therefore studied the effect of crossing mutant LRRK2 R1441G mice with tau P301S mice on tau pathology. We studied mice at 9 months of age, a time point at which the tau P301S mice have advanced-stage tau pathology. As tau pathology is quite variable from one brain area to another, we examined several areas of pathology, namely the hippocampus, the cerebral cortex and the spinal cord. We performed western blots with three antibodies recognizing important pathologic phospho-tau epitopes (AT8 recognizing S202 and T205, PHF1 recognizing S396 and S404 and CP13 recognizing S202) and normalized them to a total tau antibody (DA9). There was no significant increase in tau phosphorylation in the LRRK2 R1441G/tau P301S mice when compared with the tau P301S mice (Fig. 4) . We also performed extensive AT8 staining and quantification of tissue immunoreactivity in sections from the hippocampal CA1 region, the ventral midbrain and the spinal cord, which are areas of prominent tau pathology in tau P301S mice. We did not find significant differences between tau P301S and LRRK2 R1441G/tau P301S mice (Fig. 5) .
These findings show that LRRK2 is not an important regulator of tau phosphorylation and pathology in vivo.
LRRK2 and tau do not exert a synergistic effect in compromising the nigrostriatal dopaminergic system PD is typically characterized by loss of SNpc dopaminergic neurons as well as the loss of dopamine content in the corpus striatum where the dopaminergic nerve terminals end (1). We therefore assessed whether the double-mutant LRRK2 R1441G/ tau P301S had evidence of compromise of the nigrostriatal system. Even though LRRK2 did not exacerbate either the mice behavior or the tau pathology, we considered the possibility that both genes might interact to impair the dopaminergic system by causing a "double-hit". We therefore performed unbiased stereological cell counts of tyrosine-hydroxylase (TH)-positive neurons in the SNpc in the four groups. TH cell counts in the four groups were comparable, and no significant differences were found between them (Fig. 6 ). The overexpression of mutant LRRK2 in the P301S mice did not cause loss of TH-positive neurons. We also performed measurements of dopamine and its metabolites in the corpus striatum using high-performance liquid chromatography (HPLC) with electrochemical analysis. Similarly, we did not find differences between the four groups in the content of dopamine and its metabolites or of indices of dopamine turnover (Fig. 7) . A typical feature of PD is the pathological accumulation of α-synuclein in PD-susceptible areas, especially the brainstem (2,51). We examined whether the combination of LRRK2 and tau mutations would cause accumulation of α-synuclein in susceptible brain regions. Western blots of extracts of the ventral midbrain and the striatum, probing for total α-synuclein ( Fig. 4A and E) , showed a statistical difference between the LRRK2 R1441G group when compared with either the tau P301S or the LRRK2 R1441G/tau P301S mice. We suspect that LRRK2 might induce α-synuclein transcription as previously reported (52), possibly through activation of ERK signaling. The fact that this is not seen in double transgenic mice could be an effect of tau overexpression or due to crossing mice with different backgrounds. There was no difference between tau P301S and LRRK2 R1441G/ tau P301S. These data show that LRRK2 does not interact with tau to damage the nigrostriatal dopaminergic system.
Neurodegeneration and inflammation are not exacerbated in LRRK2/tau double transgenic mice
We next sought to assess markers of neurodegeneration in different brain areas. P301S tau mice show prominent microgliosis and astrogliosis as early as 3-4 months of age (47) . Microglial activation precedes tau deposition and contributes to the neurodegenerative process. We stained brain sections from the hippocampal CA1 field, the amygdala and the spinal cord with a CD11b antibody that recognizes activated microglia. We found prominent microglial activation in the tau P301S and LRRK2 R1441G/tau P301S mice when compared with WT or LRRK2 R1441G mice, but on quantification there were no significant differences between the tau P301S and LRRK2 R1441G/ tau P301S mice (Fig. 8) . Similarly, we stained the same brain regions with an antibody to glial fibrillary acidic protein (GFAP), a marker for astroglial activation. We found increased astrogliosis in the mutant P301S tau mice but there was no difference in the intensity or distribution of GFAP immunostaining signal with or without the presence of mutant LRRK2 (Fig. 9) . Tau P301S mice also show prominent cell loss in the hippocampus and the spinal cord, which partially accounts for the memory deficit and the progressive hindlimb paralysis. We performed unbiased stereological counts in the CA3 region of the hippocampus stained with NeuN, a neuronal somatic marker, in the four groups. Compared with WT mice, there was around a 30% cell loss in the P301S tau mice as well as in the LRRK2 R1441G/tau P301S mice, but there was no statistical difference between these two groups (Fig. 5 ). LRRK2 R1441G mice had CA3 cell counts similar to those of WT mice. We also stained spinal cord sections with cresyl violet (Nissl stain) and performed unbiased stereological cell counts of anterior horn motor neurons in the four groups. There was a highly significant 50% loss of motor neurons in tau P301S mice and in LRRK2 R1441G/tau P301S mice when compared with WT mice. The antibodies, neither in the cortex (A and B, with quantification in F and G) nor in the hippocampus (C and D, with quantification in H and I). The signals from AT8 and CP13, antibodies against pathological phospho-tau epitopes, are normalized to DA9, an antibody against total tau. α-Synuclein levels are higher in cortices of LRRK2 R1441G compared with tau P301S and LRRK2 R1441G/tau P301S mice (A and E). Data are plotted as mean ± SEM (n = 4 and 5). Statistical analysis was performed by t-test for comparison between two groups and by ANOVA for multiple groups, followed by Tukey's post-hoc test. kDA, kilodaltons.
LRRK2 R1441G mice had cell counts similar to WT mice. These findings demonstrate that LRRK2 does not exacerbate tau pathology in the hippocampus, amygdala or spinal cord.
Discussion
In our study, we assessed the possible interaction between LRRK2 and tau proteins in contributing to neurodegeneration in vivo. Specifically, we tested whether the overexpression of the common pathogenic R1441G mutation of LRRK2 would influence the behavioral phenotype and survival of transgenic mice with the P301S mutation, produce degeneration in the substantia nigra neurons and/or exacerbate tau protein abnormalities. The PS19 line of P301S tau mice that we utilized is a robust model of tau-induced neurodegeneration: the mice develop paralysis, memory deficits, tau-immunoreactive inclusions, neurodegenerative changes including hippocampal and spinal cord cell loss and premature death (47) . The R1441G LRRK2 transgenic mice were reported to develop a levodopa-responsive slowness of movement, as well as tau hyperphosphorylation and phospho-tau-positive axonal deposits in the dorsal striatum (38) . In these mice, although the level of LRRK2 protein overexpression was similar to that previously reported and the mutation was present on the gene when we sequenced it, we did not observe the behavioral phenotype that was previously reported nor did we detect the phospho-tau-positive axonal deposits in the striatum. The presence of the mutation validates the model as a useful one for testing the interplay between LRRK2 and tau. Our results show that the combination of mutant LRRK2 R1441G and tau P301S did not worsen the motor or memory deficits, which occur in the P301S tau mice, nor did it affect their survival. Moreover, there was no exacerbation of the biochemical and pathological abnormalities of tau protein, or in concomitant signs of neurodegeneration. Importantly, the nigrostriatal system did not show degeneration or signs reminiscent of PD such as the accumulation of α-synuclein.
Several lines of evidence previously suggested a pathological interaction between LRRK2 and tau. First, several reports of LRRK2-mutant PD patients describe brain tau pathology without Lewy body or α-synuclein pathology. Second, several mutant-LRRK2 animal models including mice, rats and Drosophila develop tau pathology, and work done in Drosophila and C. elegans suggests that LRRK2 and tau interact to increase neuronal susceptibility to degeneration (44) (45) (46) . Furthermore, to our knowledge, none of the LRRK2 animal models made to date develops α-synuclein pathology. Third, genetic variation in tau was confirmed in numerous GWAS studies to be an important risk factor for PD, and given the fact that LRRK2 is the most important cause of both genetic and sporadic PD, it is plausible that the two genes may interact in humans to confer vulnerability to developing PD. Also α-synuclein increased the fibrillation of tau in vitro and vice versa, and there is often considerable co-staining of tau with α-synuclein in PD brains (53) . Since α-synuclein is the preponderant pathology in LRRK2 patients, the relationship between LRRK2 and α-synuclein could reasonably involve tau. Fourth, LRRK2 was reported by different groups to bind to and affect microtubule assembly and structure, and the compartmentalization and function of tau are tightly linked to microtubules. It is therefore reasonable to expect that LRRK2 mutations, by affecting microtubule structure and function, might affect tau dynamics. Despite these prior findings, our results clearly suggest that this interaction does not occur in vivo.
Tau hyperphosphorylation and aggregation are present in a wide variety of neurodegenerative diseases including AD, frontotemporal dementias, FTDP-17, PD, amyotrophic lateral sclerosis (ALS), as well as in a range of metabolic derangements including disorders of lipid accumulation (such as Niemann-Pick type C and San Filippo disease), hypoxia, hypoglycemia, hypothermia, Figure 5 . Extensive pathological analysis of phospho-tau AT8 staining in multiple sections from hippocampal CA1, the ventral midbrain and the gray matter of the lumbar spinal cord showed no difference in pattern, intensity or extent of AT8 signal between tau P301 and LRRK2 R1441G/tau P301S at 9 months of age. Prominent AT8 staining of these regions is shown in both tau P301S and LRRK2 R1441G/tau P301S mice, whereas there was no AT8 staining in WT and LRRK2 R1441G mice. Bars: 100 µm. At least three sections per region of interest were analyzed and quantified for each mouse (n = 4). and anesthesia (18) . Therefore, tau aggregation and phosphorylation is triggered by an array of disturbances. Tau contributes differently to disease pathogenesis in each situation. In AD, tau is an essential mediator of the pathogenic effects of amyloid-beta; amyloid-beta lies upstream of tau and exacerbates its hyperphosphorylation and aggregation (21, 54, 55) . This is an essential step of the cascade of amyloid pathogenesis; the absence of tau protects mice and neurons from the detrimental effects of amyloid-beta. On the other hand, tau does not contribute to the development of phenotype in ALS mice, and tau genotype variation does not affect the progression of the human disease (56) . Therefore, tau clearly plays different roles in different neurodegenerative diseases.
It is possible that a pathophysiological relationship between LRRK2 and tau still exists but our experiments failed to show due to conceptual or technical shortcomings. One possibility is that LRRK2 and tau might be expressed in different cell types in the brain, so that they cannot interact to show a synergistic effect. This is unlikely since tau is ubiquitously expressed in all neuronal subtypes, and under the prion promoter in the P301S tau model, its expression should be in all central nervous system cells. LRRK2, under the control of its natural promoter using a BAC, is also expressed in most brain areas. Another caveat is that the interaction suggested by GWAS studies is between WT LRRK2 and tau, whereas our experiments explore an interaction between pathologically mutant overexpressed genes. Another confounder is that the tau pathology in the P301S tau mice is prominent in the spinal cord, and these mice die prematurely at the age of 10-12 months due to wasting and hindlimb paralysis from spinal cord degeneration. This may occur at a time point before tau and LRRK2 can cause enough damage to the nigral dopaminergic cells and therefore preventing us from seeing a pathologic interaction between LRRK2 and tau in the nigrostriatal system.
Recent work showed that LRRK2 and α-synuclein do not interact to exacerbate neuropathology (33,57), although there was one significantly in number in tau P301S and LRRK2 R1441G/tau P301S mice but no difference is found between these two groups. Scale bars: 100 µm. Data are plotted as mean ± SEM (n = 4-5). Statistical analysis was performed using ANOVA, followed by Tukey's post-hoc test. (*P < 0.05, **P < 0.01, ***P < 0.001). TH, tyrosine hydroxylase; SNpc, substantia nigra pars compacta. (32) . The interaction in the latter study, done under CAMKII-tTA conditional expression, may only occur in the forebrain, but not in the brainstem neurons pertinent to PD. Similarly, a knockout of tau does not significantly change the progression of the pathology or behavior in α-synuclein mice, arguing against an interaction between tau and α-synuclein in the development of PD (58) .
Human Molecular
In summary, our study shows that mutations in LRRK2 and tau do not interact in vivo to exacerbate each other's pathological effects, which suggests that they have independent roles in the development of PD. The presence of tau deposits in LRRK2 patients and animal models may be an epiphenomenon without pathological significance, or it may be a cellular protective mechanism, which occurs as neurons degenerate. Other recent studies also show no in vivo interaction between LRRK2 and α-synuclein (57), or between tau and α-synuclein (58) . These findings are important in understanding the neurodegenerative process occurring in PD, as well as in the development of new therapeutics since it may be necessary to target several pathways, which play critical roles in PD pathogenesis.
Materials and Methods

Generation of double-mutant mice overexpressing human LRRK2 R1441G and tau P301S transgenes
The generation of the lines of mice that express BAC hLRRK2 R1441G and the mice that express human tau P301S under the mouse prion protein promoter have been described previously (38, 47) . Double transgenic mice carrying both these transgenes were generated by crossbreeding the two mouse lines. The result of the breeding gave the four expected genotypes of heterozygous animals at expected ratios of around 25% each group, namely: WT, LRRK2 R1441G, tau P301S and double transgenic mice carrying both LRRK2 R1441G and tau P301S. Age-matched littermate mice from the four different genotypes of mice were used for experiments. All procedures involving animals were approved by the Institutional Animal Care Committee of Weill Cornell Medical College, New York.
Behavioral experiments and survival analysis
Rotarod testing was performed by putting each mouse separately on a rotarod which accelerates from 0 to 40 rpm over 5 min. Mice were trained for 1 day and then tested for 3 subsequent days for the time spent on the rotarod as a measure of motor ability and coordination. Openfield testing was performed by placing mice in a Plexiglas box (45 cm × 45 cm) and monitoring their movement using a video tracking system (Ethovision 3.0, Noldus Technology, Attleborough, MA, USA). Total distance moved, speed of movement and number of rearings during 5 min were analyzed. Fear conditioning was performed as follows. Day 1: training. Mice were placed in specially designed chambers, left to accommodate to the new environment for 2 min, exposed to a 30 s tone at 70 db, followed by a 20 s gap, followed by a 2 s electric shock to the floor at 0.7 mA. The shock is followed by a 1 min gap, and the whole sequence is repeated five times. Day 2: contextual fear conditioning. Mice were scored for percentage of freezing time during 3 min in the same chamber. Day 3: cued fear conditioning. Mice were scored for percentage of freezing time during the same paradigm of sound tones (without electric shock) but in a novel context where we changed the odor and floor texture of the chamber. Animal survival was assessed using Kaplan-Meier analysis.
Tissue extraction, western blot analysis and tau solubility assay
Brain tissue for biochemical analysis was obtained through rapid dissection of brain structures and snap freezing in liquid nitrogen. For western blot analysis, tissues were processed in radioimmunoprecipitation buffer (Sigma) with addition of protease inhibitors (Roche) and phosphatase inhibitor cocktails (Sigma). Tissues were sonicated, centrifuged and the supernatant used for protein analysis. The protein concentration was determined using the bicinchoninic acid protein assay (Bio-Rad) per the manufacturer's instructions. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Invitrogen) and wet-blotted to BioTrace PVDF membrane (PALL). Blots were incubated in the following primary antibodies: total tau tau-5 (Abcam), human tau HT7 MN1000 (Thermo Scientific), phospho-tau AT8 (Thermo Scientific), phospho-tau PHF1, CP13 and MC1 (generous gifts from Dr Peter Davies), LRRK2 (Epitomics), α-synuclein C-20 (Santa Cruz Biotechnology), β-actin (Sigma), horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence solutions (Amersham Biosciences). Chemiluminescence was visualized using Hyperfilm (Amersham Biosciences). For densitometric analysis, films were scanned, and densitometry analysis performed using ImageJ. Statistical analysis was performed using the ratios of the densitometric value of each band and its corresponding actin control. Tau solubility assay was performed as previously described by de Calignon et al. (59) .
Immunohistochemistry
Immunohistochemical analysis was performed by intra-cardiac perfusion of mice with ice-cold phosphate-buffered saline (PBS), pH 7.4, and 4% paraformaldehyde/PBS, pH 7.4. Brains were removed and postfixed for 3 days. Coronal sections of Figure 8 . CD11b staining, a marker of activated microglia, a prominent feature in the tau P301S mice, was performed on sections from the cerebral cortex, the hippocampal CA1 and the spinal cord. Staining showed prominent microgliosis in sections from tau P301S and LRRK2 R1441G/tau P301S mice versus WT and LRRK2 R1441G mice. Analysis of multiple sections in each region showed no difference in staining between tau P301S and LRRK2 R1441G/tau P301S (n = 4). Figure 9 . GFAP-staining (glial fibrillary acidic protein), a marker of astrocyte proliferation, which is prominent in the tau P301S mice, was performed on sections from the cerebral cortex, the hippocampal CA1 and the spinal cord. Staining showed prominent activation in sections from tau P301S and LRRK2 R1441G/tau P301S mice versus WT and LRRK2 R1441G mice. Extensive analysis of multiple sections in each region showed no difference in staining between tau P301S and LRRK2 R1441G/tau P301S (n = 4).
Human Molecular Genetics, 2015, Vol. 24, No. 12 | 3553 35 μm thickness were cut. Free-floating sections were incubated in 3% H 2 O 2 , then in 1% bovine serum albumin/0.2% Triton X-100 in PBS, then incubated with primary antibody against mouse phospho-tau AT8 (Thermo Scientific), rabbit tyrosine hydroxylase (Calbiochem), GFAP, CD11b, NeuN, followed by incubations with biotin-conjugated anti-rabbit or anti-mouse antibody (goat polyclonal; Jackson ImmunoResearch), ABC reagents (Vector Laboratories) and DAB Peroxidase Substrate (Sigma). For AT8 antibody, MOM Kit (Mouse-On-Mouse, Vector Labs) was used prior to primary antibody incubation, according to manufacturer's instructions.
Cell counting
Staining was performed on every third section of each brain structure cut at 35 μm. Cells were counted using the stereological method of the optical fractionator from the Stereo Investigator software v. 9.12 (Microbrightfield). Dopaminergic SNpc neurons were labeled with TH antibody, and seven sections were counted encompassing the whole SNpc. Spinal motor neurons were labeled by Nissl staining and identified by morphology. Sections from the beginning of the lumbosascral plexus were obtained, and neurons were counted in the anterior horns. Hippocampal CA1 and CA3 neurons were labeled with NeuN antibody and the area of interest marked, and sections were counted.
HPLC electrochemical analysis
Biogenic amines in the corpus striatum were measured by sonicating the tissue in chilled 0.1 m perchloric acid (100 μl/mg). After centrifugation (15 000g, 20 min, 4°C), 10 μl of the supernatant was isocratically eluted through a 80 × 4.6 mm C18 column (ESA) with a mobile phase containing 75 mm NaH 2 PO 4 , 1.5 mm octane sulfonic acid, 5% acetonitrile, pH 3.0 and detected by a two-channel Coulochem II electrochemical detector (ESA) kept at a potential of 0.7 mV. Data were collected and processed using external standards for respective amines on an EZChrome Elite Client Workstation (ESA). Data were normalized by protein concentration.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed by t-test for comparison between two groups and by analysis of variance (ANOVA) for multiple groups, followed by Tukey's post-hoc test. Survival analysis was performed using Kaplan-Meier curves and the log-rank (Mantel-Cox) test. Differences were considered significant with P < 0.05.
